Glucagon Receptor Antagonists: Why They Failed
Glucagon Biology
-1.6% HbA1c
The glucagon receptor antagonist LY2409021 reduced HbA1c by up to 1.6% in phase 2 trials, but caused significant liver fat accumulation and aminotransferase elevations that halted development.
Kazda et al., Diabetes Care, 2016
Kazda et al., Diabetes Care, 2016
View as imageThe logic was simple: glucagon raises blood sugar, so blocking the glucagon receptor should lower it. Multiple pharmaceutical companies pursued this strategy through the 2000s and 2010s, developing small molecules and antibodies that antagonized the glucagon receptor (GCGR). The compounds worked. LY2409021 (Eli Lilly) reduced HbA1c by up to 1.6% in phase 2 trials.[1] MK-0893 (Merck) lowered fasting glucose dose-dependently. REMD-477 (now volagidemab) reduced insulin requirements in type 1 diabetes. But every glucagon receptor antagonist that entered clinical trials encountered the same problems: liver fat accumulation, LDL cholesterol increases, and compensatory alpha cell hyperplasia. The field did not abandon glucagon targeting. It reversed direction entirely, pivoting from blocking glucagon receptors to activating them in combination with GLP-1, producing the dual and triple agonists (survodutide, retatrutide, mazdutide) now in late-stage development. For the full glucagon biology overview, see our cluster pillar.
Key Takeaways
- LY2409021 reduced HbA1c by 0.65-1.6% in phase 2 trials across 12 and 24 weeks in type 2 diabetes, confirming glucagon receptor blockade lowers blood sugar (Kazda et al., Diabetes Care, 2016)
- All glucagon receptor antagonists caused increased hepatic fat fraction, with LY2409021 producing significant liver fat accumulation and aminotransferase elevations that reversed after drug washout (Kazda et al., 2016)
- MK-0893 (Merck) increased LDL cholesterol through enhanced cholesterol absorption, a class-wide effect linked to glucagon's role in bile acid metabolism
- Compensatory alpha cell hyperplasia occurred consistently, as loss of glucagon signaling triggered a feedback loop increasing glucagon secretion 4-13 fold above baseline
- The field pivoted to glucagon receptor agonism: survodutide (GCGR/GLP-1R dual agonist) achieved 25% body weight reduction in preclinical models, exceeding semaglutide alone (Thomas et al., 2024)
- Retatrutide (triple GIP/GLP-1/glucagon agonist) reduced body weight by up to 24.2% in phase 2 human trials, validating the strategy of harnessing glucagon's energy expenditure effects rather than blocking them (Urva et al., Lancet, 2022)
The rationale: why block glucagon?
Glucagon is a 29-amino acid peptide hormone secreted by alpha cells in the pancreatic islets. Its primary role is maintaining blood glucose during fasting by stimulating hepatic glucose production through glycogenolysis (breaking down glycogen) and gluconeogenesis (synthesizing new glucose from non-carbohydrate precursors). In type 2 diabetes, glucagon secretion is inappropriately elevated, contributing to fasting and postprandial hyperglycemia. Roger Unger proposed in the 1970s that diabetes was as much a disease of glucagon excess as insulin deficiency, a concept that has gained substantial support.
Blocking glucagon signaling at its receptor seemed like a direct approach: reduce the hormonal signal that tells the liver to produce glucose. Unlike insulin-based therapies, glucagon receptor antagonism would not cause hypoglycemia in theory, because the blockade only prevents glucagon-driven glucose output without actively forcing glucose into cells.
The clinical development programs
LY2409021 (Eli Lilly)
LY2409021 was the most extensively studied small-molecule glucagon receptor antagonist. Kazda et al. (2016) reported results from both 12-week and 24-week phase 2 studies in patients with type 2 diabetes on metformin.[1]
At 12 weeks, HbA1c reductions ranged from 0.65% to 0.83% across doses. At 24 weeks, reductions ranged from 0.45% to 0.92%. Fasting plasma glucose decreased significantly. The glucose-lowering efficacy was real and clinically meaningful, comparable to some DPP-4 inhibitors.
But three safety signals emerged:
Liver fat accumulation: Hepatic fat fraction increased significantly with LY2409021 versus both placebo and the active comparator sitagliptin. Glucagon normally promotes hepatic lipid oxidation. Blocking this signal caused fat to accumulate in hepatocytes.
Aminotransferase elevations: Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) increased, indicating hepatocellular stress. These elevations reversed after drug washout, suggesting the liver injury was functional rather than structural, but the signal was sufficient to raise regulatory concerns.
Compensatory glucagon rise: Fasting glucagon levels increased substantially, reflecting alpha cell compensatory secretion in response to blocked signaling. This feedback loop raised concerns about long-term alpha cell hyperplasia.
MK-0893 (Merck)
Merck's small-molecule glucagon receptor antagonist MK-0893 reached phase 2 trials and demonstrated dose-dependent fasting glucose reductions. However, it revealed an additional class-wide liability: LDL cholesterol elevation.
Glucagon promotes bile acid synthesis by upregulating cholesterol 7-alpha-hydroxylase (CYP7A1) in the liver. Blocking glucagon signaling reduced bile acid production, which in turn increased intestinal cholesterol absorption and raised circulating LDL. The LDL increases were dose-dependent and occurred on top of the liver fat signal, making the cardiovascular risk profile unfavorable. Merck discontinued development.
REMD-477 / Volagidemab
REMD-477 (later named volagidemab) took a different approach: rather than a small molecule, it was a fully human monoclonal antibody against the glucagon receptor. It was tested in type 1 diabetes, where the rationale was that blocking glucagon could reduce glucose excursions and lower insulin requirements without the hepatic fat concerns seen with complete receptor blockade.
In a randomized controlled trial of 21 patients with type 1 diabetes, REMD-477 reduced insulin requirements and improved glycemic control over 12 weeks. The approach was novel for type 1 diabetes, where glucagon counter-regulation contributes to glycemic instability. However, the same alpha cell hyperplasia signal appeared, and the program's progress has been limited.
Why every glucagon antagonist hits the same wall
The safety problems are not drug-specific. They reflect the biology of glucagon receptor signaling.[2][3]
The liver fat problem
Glucagon drives hepatic fatty acid oxidation. When glucagon signaling is blocked, the liver loses a major stimulus for burning fat. Incoming fatty acids from the diet and peripheral lipolysis accumulate as triglycerides in hepatocytes. This is not a side effect that can be engineered away with better drug design. It is a direct consequence of removing glucagon's metabolic function in the liver.
The irony is significant: many patients with type 2 diabetes already have non-alcoholic fatty liver disease (NAFLD/MASH). A diabetes drug that worsens hepatic steatosis is moving in the wrong direction for the comorbid condition that affects 60-70% of this population.
The alpha cell hyperplasia problem
The pancreatic alpha cell has a negative feedback loop: glucagon receptor signaling in the liver generates signals (including bile acids and amino acids) that feed back to suppress alpha cell proliferation and glucagon secretion. When this feedback is interrupted by receptor blockade, alpha cells proliferate and glucagon secretion increases dramatically, sometimes 4-13 fold above baseline.
In animal models with genetic glucagon receptor knockout, alpha cell hyperplasia progresses to the point of forming glucagonomas (glucagon-secreting tumors). Whether this would occur with chronic pharmacological antagonism in humans is unknown, but the preclinical signal was sufficient to concern regulators and investigators alike.[4]
The LDL cholesterol problem
Glucagon's role in bile acid synthesis means that blocking the receptor reduces the conversion of cholesterol to bile acids. The cholesterol that would have been converted to bile acids instead enters the circulation as LDL. This effect was consistent across chemical classes (small molecules and antibodies) and dose ranges, confirming it as a mechanism-based liability.
The pivot: from antagonism to agonism
The failure of glucagon receptor antagonists taught the field something unexpected: glucagon's non-glycemic effects, particularly on energy expenditure, lipid oxidation, and body weight, were therapeutically valuable. Rather than blocking glucagon, the new strategy became activating glucagon receptors in combination with GLP-1 receptor activation, using the GLP-1 component to counteract glucagon's hyperglycemic effect while harnessing glucagon's thermogenic and lipolytic properties.
Survodutide (GLP-1/GCGR dual agonist)
Thomas et al. (2024) described how survodutide (Boehringer Ingelheim/Zealand) was selected from 19 candidate molecules based on balanced dual agonism at the GLP-1 and glucagon receptors.[5] In diet-induced obese mice, survodutide achieved 25% body weight reduction, exceeding what semaglutide achieved through GLP-1 agonism alone. The glucagon receptor activation drove increased energy expenditure and hepatic lipid oxidation, the exact opposite of what glucagon receptor antagonists caused. Survodutide is now in phase 3 trials for MASH and obesity. For more detail, see survodutide: the GLP-1/glucagon agonist targeting your liver.
Retatrutide (GLP-1/GIP/GCGR triple agonist)
Retatrutide (Eli Lilly) activates three receptors: GLP-1, GIP, and glucagon. Urva et al. (2022) published phase 1 results in the Lancet showing dose-dependent reductions in HbA1c (up to 1.6%, placebo-adjusted) and body weight (up to 8.96 kg at 12 weeks) in people with type 2 diabetes.[6] Phase 2 data showed body weight reductions of up to 24.2% at 48 weeks. The glucagon component contributed to energy expenditure and liver fat reduction without causing hyperglycemia because the GLP-1 and GIP agonism maintained glucose control. See retatrutide and liver fat for the MASH data.
Mazdutide (GLP-1/GCGR dual agonist)
Mazdutide, developed by Innovent Biologics in China, is another GLP-1/glucagon dual agonist that has entered late-stage clinical trials. Dong et al. (2025) reported on mazdutide's effects beyond metabolic control, including cognitive benefits in diabetic animal models.[7] The compound's clinical development is furthest along in China, with mazdutide representing a distinct pipeline from the Western programs.
Receptor structure: why partial agonism works
Darbalaei et al. (2023) used site-directed mutagenesis to map the specific amino acid residues in the glucagon receptor that are critical for activation by multi-target peptide agonists.[3] They found that dual agonists (MEDI0382, SAR425899) and the triple agonist (peptide 20) interact with overlapping but distinct receptor residues compared to native glucagon. This structural work explains why it is possible to design peptides that partially activate the glucagon receptor (enough for thermogenic and lipolytic effects) without fully engaging the glycogenolysis pathway. The pharmacology of partial agonism at the glucagon receptor is central to why dual agonists succeed where antagonists failed.
Finan et al. (2015) provided the foundational proof of concept by designing a rationally engineered monomeric peptide triagonist with balanced activity at GLP-1, GIP, and glucagon receptors.[4] In rodent models of obesity, the triagonist outperformed the best available dual coagonists and monoagonists for weight reduction, glycemic control, and reversal of hepatic steatosis. Genetic knockout experiments confirmed that removing any one of the three receptor targets diminished efficacy, demonstrating that all three pathways contributed independently to the metabolic benefit. This study established the intellectual foundation for retatrutide's clinical development.
Lessons from the glucagon antagonist era
The glucagon receptor antagonist story illustrates a broader principle in peptide pharmacology: hormones evolved as integrated signaling systems, not isolated switches. Blocking glucagon receptor signaling removed not just the undesirable glucose-raising effect but also the desirable effects on lipid metabolism, energy expenditure, and alpha cell regulation. The resulting phenotype, fatty liver with elevated LDL and hyperplastic alpha cells, was worse than the disease being treated.
The dual agonist approach respects the system's complexity. By activating glucagon receptors alongside GLP-1 receptors, the metabolic benefits of glucagon (increased energy expenditure, hepatic fat reduction, thermogenesis) are captured while the hyperglycemic effect is counteracted by GLP-1's insulin-stimulating and glucagon-suppressing actions. This is not a compromise. In preclinical and early clinical data, dual agonists outperform single GLP-1 agonists for both weight loss and liver fat reduction, producing results that neither pathway achieves alone.[8] For context on how GLP-1 and GIP signaling complement glucagon biology, see GLP-1 and GIP: the two incretins and why they matter.
The Bottom Line
Glucagon receptor antagonists effectively lowered blood sugar in type 2 diabetes but were derailed by mechanism-based toxicities: hepatic fat accumulation, LDL cholesterol elevation, and alpha cell hyperplasia. Three separate development programs (LY2409021, MK-0893, REMD-477) encountered the same problems, confirming these as class-wide liabilities inherent to blocking glucagon signaling. The field reversed course, and the current generation of glucagon-targeting drugs (survodutide, retatrutide, mazdutide) activate rather than block the glucagon receptor, using co-agonism with GLP-1 to harness glucagon's metabolic benefits while preventing hyperglycemia.